
SARCOMA
Latest News

Neoadjuvant Eftilagimod Alfa Regimen Yields 81% 12-Month DFS in Soft Tissue Sarcoma
Video Series

Latest Videos
Shorts
Podcasts
CME Content
More News

VIR-5500 and [²¹²Pb]PSV359 received FDA fast track designations for prostate cancer and solitary fibrous tumors, respectively.

LRRC15-targeting ADC SOT106 gains FDA fast track and orphan status for sarcomas, showing preclinical promise as it heads into a first-in-human trial.

During a live event, Seth M. Pollack, MD, and participants discussed how the practical burden of toxicity monitoring is increasingly steering the choice between systemic therapies for recurrent diffuse tenosynovial giant cell tumor.

OST-HER2, an investigational immunotherapy, yielded favorable overall survival outcomes ahead of an FDA meeting to consider its basis for approval.

The LRRC15-targeting antibody-drug conjugate will be investigated in a first-in-human trial later this year.

FDA reviews OST-HER2 survival data for potential accelerated approval for preventing recurrent metastatic osteosarcoma after lung surgery.

Damon R. Reed, MD, compared the carefully considered off-label use of trastuzumab deruxtecan with a clinical trial experience in 2 rare sarcoma subtypes.

A B7-H3–targeted antibody-drug conjugate showed benefit vs chemotherapy in relapsed osteosarcoma.

Results of a retrospective study suggest that response to immune checkpoint inhibitors in sarcoma may be linked to other factors besides level of tumor mutational burden or mismatch repair deficiency.

An oral combination of sirolimus and domatinostat is being used to treat patients with metastatic osteosarcoma and other sarcomas.

The FDA set a PDUFA date of April 28, 2027 for approval of the gamma secretase inhibitor for progressing desmoid tumors.

During a live event, Brittany Siontis, MD, discussed a case of a 50-year-old patient with an actively growing desmoid tumor.

Results from the SPEARHEAD-1 trial supported FDA approval of the engineered T-cell product for patients as young as 12 years of age.

During a live event, Brittany Siontis, MD, discussed treatment strategies for a patient with a progressive abdominal desmoid tumor.

The FDA set a target date of April 14, 2027 to review ozekibart as targeted treatment for chondrosarcoma.

Alembic receives tentative FDA approval for generic larotrectinib capsules, a TRK inhibitor for NTRK fusion–positive solid tumors, with potential 180-day exclusivity.

A first-in-human trial of the antibody-drug conjugate is planned for later this year.

ctDNA clearance and baseline detectability emerge as prognostic markers in the StrateGIST 1 trial; favorable ORRs seen in early-line cohorts.














































